CureVac (CVAC) Stock Analysis: AI Score & Alternative Data
CVAC alt-data: web traffic climbing, business outlook lagging
Is CureVac a buy right now? The alternative data says hold. This CVAC stock analysis is built on the 25+ alternative data signals AltIndex tracks on CureVac every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $4.66 with a $1B market cap.
The bullish side of the 90-day ledger: web traffic up 27.0% to 8K monthly visits. The drag: just 24% of employees report a positive business outlook. That tension is what keeps the score mid-range.
CVAC’s broader alt-data profile also covers headcount (660 employees, according to LinkedIn), and X followers (18K). Every signal links to its own page with full history, the CVAC technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on CVAC is just below.
CureVac AI Stock Analysis
CureVac is a biotechnology company engaged in the development of transformative medicines using its proprietary messenger RNA (mRNA) technology. The company's products encompass vaccines for infectious diseases, oncology treatments, and protein therapies across a range of medical conditions.
Analysis generated October 7, 2026.
Recent CureVac Stock Alerts
|
CureVac | July 6 Employee Rating is down by 2.9% over the last month. |
|
CureVac | June 15 Business Outlook among employees is down by 4% over the last month. |
|
CureVac | March 16 Employee Rating is up by 6.3% over the last month. |
|
CureVac | January 17 Business Outlook among employees is down by 10.7% over the last month. |
CureVac Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 8K | 27.0% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 660 | 0% | |
| Wikipedia Views | 17 | 6.3% | |
| Employee Recommend | 37 | 0% | |
| Business Outlook | 24 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 0% | |
| Stocktwits Mentions | 0 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 6K | 0.7% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 18K | 0% | |
| Youtube Subscribers | 609 | 0% |
About CureVac (CVAC)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
| Price | $4.66 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $1B |
| Year Range | $4 – $5 |
| Dividend Yield | 0% |
| PE Ratio | 7.0 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest CureVac News
View more → |
Psychological OperationOctober 8 - Activistpost.com |
 |
Europe's new holiday sensation! Our insider guide to the tiny, affordable country British tourists are flocking to - and the medieval towns, mountains and spectacular lakes you MUST seeSeptember 13 - Dailymail.com |
 |
mRNA’s second act: A bespoke cancer vaccine & what Merck-Moderna’s melanoma trial could mean for oncologyAugust 19 - Hindustan Times |
BioNTech Announces Second Quarter 2026 Financial Results and Corporate UpdateAugust 4 - GlobeNewswire |
|
Moderna Stock Has Doubled in 2026, But Wall Street Still Isn’t ConvincedJuly 29 - Yahoo Entertainment |
See CureVac’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for CVAC, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREECureVac Earnings & Financial Performance
View all earnings →CureVac Insider Trading Activity
View all →| No recent insider transactions on file. |
CureVac Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to CureVac
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Castle BiosciencesCSTL |
$33.49 2.7% | $1B | 61 |
 |
MannkindMNKD |
$3.14 4.6% | $1B | 48 |
 |
MeiraGTx HldgsMGTX |
$10.59 0.9% | $1B | 41 |
 |
SavaraSVRA |
$4.82 2.0% | $1B | 47 |
 |
Aktis OncologyAKTS |
$17.57 3.2% | $1B | 55 |
Explore CureVac Data
Frequently Asked Questions: CureVac (CVAC)
CureVac has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of CureVac (CVAC) stock is $4.66 with a market cap of $1B.
As of today, CureVac’s PE (Price to Earnings) ratio is 7.0.
View the latest CureVac insider transactions to see recent buying and selling activity by company executives and directors.
Check the CureVac congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The CVAC stock price chart above shows CureVac’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full CureVac technical analysis for RSI, moving averages, and more.
See the stocks similar to CureVac section on this page for companies in the same industry ranked by market cap and AI Score.
